Corrigendum to “Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations”[619 1 (2025) 217668 1–13](S0304383525002344)(10.1016/j. canlet. 2025.217668). 

Uemoto, Y., Lin, C. C. A., Wang, B., Ye, D., Fang, Y. V., Bikorimana, E., ... & Arteaga, C. L.